Supplementary Legal Opinion from Zhejiang Tian Ce Law Firm on Zhejiang Anglikang Pharmaceutical Co., Ltd.'s 2025 A-Share Issuance to Specific Objects (Part 1)

Supplementary Legal Opinion

Zhejiang Tian Ce Law Firm on Zhejiang Anglikang Pharmaceutical Co., Ltd.'s 2025 A-Share Issuance to Specific Objects (Part 1)

Zhejiang Tian Ce Law Firm
118 Sanxin Road, Shangcheng District, Hangzhou, Zhejiang Province
Office Building 3, 6-12 Floors, Hangzhou International Financial Center
Phone: 0571-87901111
Fax: 0571-87901500

Table of Contents

1. Declaration Matters ...............................................................................................................3
2. Main Text ............................................................................................................................4
   1. Feedback Response Section .........................................................................................4
      • Question 1 ..................................................................................................................4
      • Question 2 ................................................................................................................13
   2. Annual Report Supplementary Legal Opinion Section ................................................49
      • I. Approval and Authorization of This Issuance ....................................................49
      • II. Issuer's Qualification for This Issuance ..........................................................50
      • III. Substantial Conditions for This Issuance .......................................................50
      • IV. Independence of the Issuer ..............................................................................51
      • V. Controlling Shareholders and Actual Controllers of the Issuer .......................51
      • VI. Issuer's Capital and Evolution .........................................................................52
      • VII. Issuer's Business .............................................................................................53
      • VIII. Related Transactions and Industry Competition of the Issuer .....................55
      • IX. Major Assets of the Issuer ................................................................................57
      • X. Major Debts of the Issuer ..................................................................................61
      • XI. Major Asset Changes and Mergers of the Issuer .............................................63
      • XII. Rules of Procedure and Standard Operations of the Issuer's Shareholders' Meeting, Board of Directors, and Supervisory Board ................................................63
      • XIII. Changes in Directors, Supervisors, and Senior Management of the Issuer ....64
      • XIV. Taxation of the Issuer .....................................................................................64
      • XV. Environmental Protection and Product Quality Standards of the Issuer ........67
      • XVI. Use of Raised Funds by the Issuer ................................................................68
      • XVII. Litigation, Arbitration, or Administrative Penalties ....................................70
      • XVIII. Conclusion ....................................................................................................71

Supplementary Legal Opinion

Zhejiang Tian Ce Law Firm on Zhejiang Anglikang Pharmaceutical Co., Ltd.'s 2025 A-Share Issuance to Specific Objects (Part 1) [TCYJS2026H0868]

To: Zhejiang Anglikang Pharmaceutical Co., Ltd.

This firm has accepted the issuer's commission to act as the special legal advisor for this issuance. In accordance with the requirements of the Securities Law, Company Law, and relevant laws, administrative regulations, and the China Securities Regulatory Commission's issuance registration management measures, reporting rules, and practice rules, this firm has issued the legal opinion document numbered "TCYJS2026H0476" regarding the issuer's 2025 A-share issuance to specific objects and listing on the Shenzhen Stock Exchange (hereinafter referred to as the "Legal Opinion") and the lawyer's work report numbered "TCLG2026H0760" (hereinafter referred to as the "Lawyer's Work Report").